Reuters reported Sunday that a US District Court in New Jersey has ruled that AstraZeneca’s patent for asthma treatment Pulmicort Respules is invalid. The drugmaker is appealing the decision. . In the meantime, based on the court’s ruling, Actavis announced that it would launch a generic version of the drug, which reportedly garnered $1.1 billion in branded and generic sales from June 2013 to June 2014. Teva, under agreement with AstraZeneca, already manufactures and markets another copycat of the brand.
Court invalidates patent for AstraZeneca asthma drug
A New Jersey District Court ruled that the Pulmicort Respules patent is invalid, opening the door for Actavis to launch a generic version of the billion-dollar asthma drug.
